- Record: found
- Abstract: found
- Article: not found
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Shang-Chiung Chen
1 ,
Matts Kagedal
2 ,
Yuying Gao
3 ,
Bei Wang
2 ,
Marie-Laurence Harle-Yge
4 ,
Sandhya Girish
2 ,
Jin Jin
2 ,
Chunze Li
2
Dec 2017
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprising trastuzumab conjugated via a stable thioether linker to DM1, a highly potent cytotoxic agent. A population pharmacokinetics (PK) analysis was performed to characterize T-DM1 PK and evaluate the impact of patient characteristics on T-DM1 PK in previously treated patients with HER2-positive advanced gastric cancer (AGC).